Registry for Participants With Short Bowel Syndrome

  • End date
    May 31, 2031
  • participants needed
  • sponsor
Updated on 21 June 2021


This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.


28-MAY-2021: Enrollment of new Teduglutide treated adult participants into this study continues according to discretion and availability of sites during the COVID-19 situation, however, enrollment of untreated adult participants and pediatrics patients was stopped on the 30th April 2021 as the targets in these cohorts had been met. Enrollment of new Teduglutide treated adult participants is expected to be prolonged until 2022.

Condition Short Bowel Syndrome
Clinical Study IdentifierNCT01990040
Last Modified on21 June 2021


Yes No Not Sure

Inclusion Criteria

Male and female participants, of any age, with a diagnosis of short bowel syndrome (SBS)
Signed informed consent and medical records release by the participant or a legally acceptable representative
Participants who have never received teduglutide treatment must be on parenteral nutrition (PN)/intravenous (IV) fluids support for at least 6 months at the time of enrollment

Exclusion Criteria

Participants currently participating in a blinded clinical trial or their extension studies
Participants who have never been on PN/IV support
Participants who are currently or previously exposed to any Glucagon-like peptide 2 (GLP-2) analogs other than teduglutide
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note